TY - JOUR
T1 - Screening for Auditory Impairment - Which Hearing Assessment Test (SAI-WHAT)
T2 - RCT design and baseline characteristics
AU - Yueh, Bevan
AU - Collins, Margaret P.
AU - Souza, Pamela E.
AU - Heagerty, Patrick J.
AU - Liu, Chuan Fen
AU - Boyko, Edward J.
AU - Loovis, Carl F.
AU - Fausti, Stephen A.
AU - Hedrick, Susan C.
PY - 2007/5/1
Y1 - 2007/5/1
N2 - Background: Effective screening programs should not merely detect presence of disease, but also lead to long-term benefit. We describe the rationale and design of the first randomized clinical trial to study the long-term effects of routine screening for hearing loss. We also describe the baseline characteristics of the randomized cohort. Methods: We randomized 2305 veterans age 50 years or older to a control arm without screening, or to screening with: physiologic testing (AudioScope), a self-administered questionnaire (Hearing Handicap Inventory for the Elderly-Screening version [HHIE-S]), or both tests. The primary outcome measure will be hearing aid use one year after screening. We will also study a number of secondary outcomes, including appointments made with and visits to an audiologist, cases of aidable hearing loss, hearing aids dispensed, self-rated communication ability, and hearing-related quality of life. Results: Baseline demographic and health status measures were evenly distributed across the screening arms. The percentage of patients who screened positive for hearing loss was 18.6%, 59.2%, and 63.6% for the AudioScope, HHIE-S, and combined screening arms, respectively. Implications: Long-term results are needed to gain insight into whether the AudioScope is associated with high rates of false negative screening, the HHIE-S is associated with high rates of false positive screening, or a combination of both. Identifying the best screening program will depend on determining which strategy leads to successful hearing aid use.
AB - Background: Effective screening programs should not merely detect presence of disease, but also lead to long-term benefit. We describe the rationale and design of the first randomized clinical trial to study the long-term effects of routine screening for hearing loss. We also describe the baseline characteristics of the randomized cohort. Methods: We randomized 2305 veterans age 50 years or older to a control arm without screening, or to screening with: physiologic testing (AudioScope), a self-administered questionnaire (Hearing Handicap Inventory for the Elderly-Screening version [HHIE-S]), or both tests. The primary outcome measure will be hearing aid use one year after screening. We will also study a number of secondary outcomes, including appointments made with and visits to an audiologist, cases of aidable hearing loss, hearing aids dispensed, self-rated communication ability, and hearing-related quality of life. Results: Baseline demographic and health status measures were evenly distributed across the screening arms. The percentage of patients who screened positive for hearing loss was 18.6%, 59.2%, and 63.6% for the AudioScope, HHIE-S, and combined screening arms, respectively. Implications: Long-term results are needed to gain insight into whether the AudioScope is associated with high rates of false negative screening, the HHIE-S is associated with high rates of false positive screening, or a combination of both. Identifying the best screening program will depend on determining which strategy leads to successful hearing aid use.
KW - Depression
KW - Hearing aids
KW - Hearing loss
KW - Patient compliance
KW - Patient outcome assessment
KW - Quality of life
KW - Randomized controlled trials
KW - Rehabilitation of hearing impaired
KW - Screening
KW - Treatment effectiveness
UR - http://www.scopus.com/inward/record.url?scp=33847304014&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33847304014&partnerID=8YFLogxK
U2 - 10.1016/j.cct.2006.08.008
DO - 10.1016/j.cct.2006.08.008
M3 - Article
C2 - 17030153
AN - SCOPUS:33847304014
VL - 28
SP - 303
EP - 315
JO - Contemporary Clinical Trials
JF - Contemporary Clinical Trials
SN - 1551-7144
IS - 3
ER -